Prognostic factors associated with survival in patients with hepatocellular carcinoma undergoing transarterial chemoembolisation: an Australian multicenter cohort study

Abstract

Aim: Transarterial chemoembolisation (TACE) is recommended therapy for intermediate-stage hepatocellular carcinoma (HCC). However, the wide variations in outcomes reflect significant heterogeneity of this patient group. We evaluated the prognostic factors associated with survival in a real-world setting to identify those at high risk of a poor outcome.

Methods: Patients with HCC who underwent initial TACE at six tertiary hospitals between 2009 to 2014 were included via an extensive search of hospital databases and electronic medical records. Overall survival (OS) was measured from the date of initial treatment to the date of death or last follow-up. Univariate and multivariate Cox regression analyses were used to assess the effects of baseline variables on post-TACE survival.

Results: The majority of the 431 eligible patients were Caucasian (80%), male (87%), with a mean age of 66 years and had alcohol-related cirrhosis (43%). Most were Child-Pugh A (69%) with BCLC stage A (59%) or B (35%) disease, with a median OS of 28 months. On multivariate analysis, pre-treatment ascites (P = 0.001) and larger HCC (P < 0.001) were associated with worse overall survival, while higher serum albumin (P < 0.001) and HBV (P = 0.005) were associated with improved survival.

Conclusion: Patients with advanced liver disease, including the presence of ascites and lower serum albumin, as well as those with greater tumour burden, have poorer outcomes following TACE treatment. Such findings provide a better understanding of the variation in survival after TACE and are helpful in facilitating selection and timely stage migration of patients undergoing this therapy.

Keywords

Liver Cancer / tumour stage / unresectable hepatocellular carcinoma / transarterial chemoembolisation / treatment allocation / patient selection / treatment outcomes / prognostic factors / aetiology of liver disease / chronic hepatitis B infection / cirrhosis severity

References

[1] Bray F,Soerjomataram I,Torre LA.Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries.CA Cancer J Clin2018;68:394-424

[2] Torre LA,Ward EM.Global cancer incidence and mortality rates and trends - an update.Cancer Epidemiol Biomarkers Prev2016;25:16-27

[3] El-Serag HB,Rudolph L.Diagnosis and treatment of hepatocellular carcinoma.Gastroenterology2008;134:1752-63

[4] Sherman M.Staging for hepatocellular carcinoma: complex and confusing.Gastroenterology2014;146:1599-602

[5] Marrero JA,Bronowicki JP.The challenge of prognosis and staging for hepatocellular carcinoma.Oncol2010;15 Suppl 4:23-33

[6] Llovet JM,Bruix J.Prognosis of hepatocellular carcinoma: the BCLC staging classification.Semin Liver Dis1999;19:329-38

[7] Forner A,de Lope CR.Current strategy for staging and treatment: the BCLC update and future prospects.Semin Liver Dis2010;30:61-74

[8] Llovet JM,Pikarsky E.Hepatocellular carcinoma.Nat Rev Dis Primers2016;2:16018

[9] Raoul JL,Forner A.Evolving strategies for the management of intermediate-stage hepatocellular carcinoma: available evidence and expert opinion on the use of transarterial chemoembolization.Cancer Treat Rev2011;37:212-20

[10] Llovet JM.Systematic review of randomized trials for unresectable hepatocellular carcinoma: chemoembolization improves survival.Hepatology2003;37:429-42

[11] Roberts SK,Lubel J.Melbourne Liver GroupTreatment choice for early-stage hepatocellular carcinoma in real-world practice: impact of treatment stage migration to transarterial chemoembolization and treatment response on survival.Scand J Gastroenterol2018;53:1368-75

[12] Lo CM,Tso WK.Randomized controlled trial of transarterial lipiodol chemoembolization for unresectable hepatocellular carcinoma.Hepatology2002;35:1164-71

[13] Llovet JM,Montaña X.Arterial embolisation or chemoembolisation versus symptomatic treatment in patients with unresectable hepatocellular carcinoma: a randomised controlled trial.Lancet2002;359:1734-9

[14] Takayasu K,Kudo M.Superselective transarterial chemoembolization for hepatocellular carcinoma. Validation of treatment algorithm proposed by Japanese guidelines.J Hepatol2012;56:886-92

[15] Burrel M,Forner A.Survival of patients with hepatocellular carcinoma treated by transarterial chemoembolisation (TACE) using Drug Eluting Beads. Implications for clinical practice and trial design.J Hepatol2012;56:1330-5

[16] Marrero JA,Sirlin CB.Diagnosis, staging, and management of hepatocellular carcinoma: 2018 practice guidance by the American association for the study of liver diseases.Hepatology2018;68:723-50

[17] Mgaieth S,Gow P.Impact of viral hepatitis aetiology on survival outcomes in hepatocellular carcinoma: a large multicentre cohort study.J Viral Hepat2017;24:982-9

[18] Clark TW.Complications of hepatic chemoembolization.Semin Intervent Radiol2006;23:119-25 PMCID:PMC3036366

[19] Raoul JL,Bolondi L,Kloeckner R.Updated use of TACE for hepatocellular carcinoma treatment: how and when to use it based on clinical evidence.Cancer Treat Rev2019;72:28-36

[20] Finn RS,Farah W.Therapies for advanced stage hepatocellular carcinoma with macrovascular invasion or metastatic disease: a systematic review and meta-analysis.Hepatology2018;67:422-35

[21] Katayama K,Abe Y.Number of nodules but not size of hepatocellular carcinoma can predict refractoriness to transarterial chemoembolization and poor prognosis.J Clin Med Res2018;10:765-71 PMCID:PMC6968922

[22] Lee YH,Huang YH.Vascular invasion in hepatocellular carcinoma: prevalence, determinants and prognostic impact.J Clin Gastroenterol2014;48:734-41

[23] Lencioni R,Soulen MC,Geschwind JF.Lipiodol transarterial chemoembolization for hepatocellular carcinoma: a systematic review of efficacy and safety data.Hepatology2016;64:106-16

[24] Kwak HW,Nam BH.Clinical outcomes of a cohort series of patients with hepatocellular carcinoma in a hepatitis B virus-endemic area.J Gastroenterol Hepatol2014;29:820-9

[25] Hong TP,Fink M.Surveillance improves survival of patients with hepatocellular carcinoma: a prospective population-based study.Med J Aust2018;209:348-54

[26] Díaz-González Á,Bruix J.Treatment of hepatocellular carcinoma.Dig Dis2016;34:597-602

[27] Association for the Study of the Liver, European Association for the Study of the Liver. EASL clinical practice guidelines: management of hepatocellular carcinoma.J Hepatol2018;69:182-236

[28] Piscaglia F.Patient selection for transarterial chemoembolization in hepatocellular carcinoma: importance of benefit/risk assessment.Liver Cancer2018;7:104-19 PMCID:PMC5892363

[29] Sangiovanni A.Treatment of hepatocellular carcinoma: beyond international guidelines.Liver Int2016;36 Suppl 1:124-9

[30] Guarino M,de Stefano G.Progetto Epatocarcinoma Campania GroupAdherence to barcelona clinic liver cancer guidelines in field practice: results of progetto epatocarcinoma campania.J Gastroenterol Hepatol2018;33:1123-30